{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:21:26Z","timestamp":1793823686296,"version":"4.6.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"crossref","award":["GR-2016-02361986"],"award-info":[{"award-number":["GR-2016-02361986"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The International Parkinson\u2019s and Movement Disorder Society (MDS) criteria for progressive supranuclear palsy (PSP) have broadened the clinical spectrum of the disease and established phenotypic characterization according to the predominant manifestation at onset. The objective of this study is to describe clinical\/cognitive and imaging features of a monocentric cohort of PSP patients, highlighting different patterns of functional disability according to the assigned phenotype. We retrospectively reviewed clinical\/imaging data of 53 PSP patients diagnosed with probable PSP according to the MDS criteria and 40 age\/sex-matched healthy controls (HCs). Neurological\/neuropsychological assessments were performed using standardized scales, as well as comprehensive magnetic resonance imaging (MRI) morphometric measurements. In our cohort, there were 24\/53 PSP-RS (Richardson\u2019s syndrome), 13\/53 PSP-P (Parkinsonism), 7\/53 PSP-PGF (Progressive gait freezing), and 9\/53 PSP-Cog (Cognitive impairment). PSP-Cog presented the worst motor profiles, the highest percentages of dementia and impaired functional autonomy; 4\/9 PSP-Cog and 2\/7 PSP-PGF died. PSP-P had the lowest motor\/cognitive burden. All MRI parameters had good discriminative efficacy vs. HCs, with P\/M 2.0 discriminating PSP-PGF from PSP-RS and PSP-Cog. We highlighted discrete clinical and imaging patterns that best characterize different PSP phenotypes. PSP-Cog and PSP-PGF\/RS manifest greater incidence of dementia and motor disability, respectively, while PSP-P has a more benign course. The identification of different phenotypes may be the expression of different progression patterns requiring tailored approaches in terms of follow-up and treatment. These findings support the concept of discrete patterns of Tau pathology within the PSP spectrum and encourage research for phenotype-specific outcome measures.<\/jats:p>","DOI":"10.1007\/s00702-023-02591-z","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T12:02:45Z","timestamp":1674734565000},"page":"97-109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Clinical, cognitive, and morphometric profiles of progressive supranuclear palsy phenotypes"],"prefix":"10.1007","volume":"130","author":[{"given":"Marta","family":"Campagnolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Weis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Fogliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Cianci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Garon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Fiorenzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miryam","family":"Carecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florinda","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Bisiacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Biundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"2591_CR1","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/mds.27619","volume":"34","author":"F Ali","year":"2019","unstructured":"Ali F, Martin PR, Botha H et al (2019) Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy. Mov Disord 34:1144\u20131153","journal-title":"Mov Disord"},{"key":"2591_CR2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10072-012-1112-z","volume":"34","author":"A Antonini","year":"2013","unstructured":"Antonini A, Abbruzzese G, Ferini-Strambi L et al (2013) Validation of the Italian version of the movement disorder society-unified Parkinson\u2019s disease rating scale. Neurol Sci 34:683\u2013687","journal-title":"Neurol Sci"},{"key":"2591_CR3","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.2147\/NDT.S178263","volume":"14","author":"D Belvisi","year":"2018","unstructured":"Belvisi D, Berardelli I, Suppa A et al (2018) Neuropsychiatric disturbances in atypical parkinsonian disorders. Neuropsychiatr Dis Treat 14:2643\u20132656","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2591_CR4","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","volume":"16","author":"AL Boxer","year":"2017","unstructured":"Boxer AL, Yu JT, Golbe LI et al (2017) Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 16:552\u2013563","journal-title":"Lancet Neurol"},{"key":"2591_CR5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/mds.25872","volume":"29","author":"JR Burrell","year":"2014","unstructured":"Burrell JR, Hodges JR, Rowe JB (2014) Cognition in corticobasal syndrome and progressive supranuclear palsy: a review. Mov Disord 29:684\u2013693","journal-title":"Mov Disord"},{"key":"2591_CR6","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1212\/WNL.48.5_Suppl_6.10S","volume":"48","author":"JL Cummings","year":"1997","unstructured":"Cummings JL (1997) The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology 48:S10\u2013S16","journal-title":"Neurology"},{"key":"2591_CR7","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1002\/mds.21844","volume":"22","author":"B Dubois","year":"2007","unstructured":"Dubois B, Burn D, Goetz C et al (2007) Diagnostic procedures for Parkinson\u2019s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314\u20132324","journal-title":"Mov Disord"},{"key":"2591_CR8","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00702-016-1589-3","volume":"123","author":"E Fiorenzato","year":"2016","unstructured":"Fiorenzato E, Weis L, Falup-Pecurariu C et al (2016) Montreal cognitive assessment (MoCA) and mini-mental state examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy. J Neural Transm (vienna) 123:1435\u20131442","journal-title":"J Neural Transm (vienna)"},{"key":"2591_CR9","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00702-019-02065-1","volume":"126","author":"E Fiorenzato","year":"2019","unstructured":"Fiorenzato E, Antonini A, Camparini V et al (2019) Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson\u2019s disease. J Neural Transm (vienna) 126:1437\u20131445","journal-title":"J Neural Transm (vienna)"},{"key":"2591_CR10","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1093\/brain\/awm032","volume":"130","author":"LI Golbe","year":"2007","unstructured":"Golbe LI, Ohman-Strickland PA (2007) A clinical rating scale for progressive supranuclear palsy. Brain 130:1552\u20131565","journal-title":"Brain"},{"key":"2591_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/01.NAJ.0000314810.46029.74","volume":"108","author":"C Graf","year":"2008","unstructured":"Graf C (2008) The Lawton instrumental activities of daily living scale. Am J Nurs 108:52\u201362","journal-title":"Am J Nurs"},{"key":"2591_CR12","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/mds.27666","volume":"34","author":"MJ Grimm","year":"2019","unstructured":"Grimm MJ, Respondek G, Stamelou M et al (2019) Movement Disorder Society-endorsed PSP Study Group. How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Mov Disord 34:1228\u20131232","journal-title":"Mov Disord"},{"key":"2591_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.parkreldis.2021.01.015","volume":"84","author":"M Guasp","year":"2021","unstructured":"Guasp M, Molina-Porcel L, Painous C et al (2021) Association of PSP phenotypes with survival: a brain-bank study. Parkinsonism Relat Disorders 84:77\u201381","journal-title":"Parkinsonism Relat Disorders"},{"key":"2591_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26987","volume":"32","author":"G Hoglinger","year":"2017","unstructured":"Hoglinger G, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord 32:853864","journal-title":"Mov Disord"},{"key":"2591_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1001\/jamaneurol.2019.4347","volume":"77","author":"E Jabbari","year":"2020","unstructured":"Jabbari E, Holland N, Chelban V et al (2020) Diagnosis across the spectrum of progressive supranuclear palsy and corticobasal syndrome. JAMA Neurol 77:377\u2013387","journal-title":"JAMA Neurol"},{"key":"2591_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/135581969700200105","volume":"2","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson C, Layte R (1997) Development and testing of the UK SF-12 (short form health survey). J Health Serv Res Policy 2:14\u201318","journal-title":"J Health Serv Res Policy"},{"key":"2591_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2190\/UURL-2RYU-WRYD-EY3K","volume":"6","author":"S Katz","year":"1976","unstructured":"Katz S, Akpom CA (1976) A measure of primary sociobiological functions. Int J Health Serv 6:493\u2013508","journal-title":"Int J Health Serv"},{"key":"2591_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00401-020-02158-2","volume":"140","author":"GG Kovacs","year":"2020","unstructured":"Kovacs GG, Lukic MJ, Irwin DJ et al (2020) Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol 140:99\u2013119","journal-title":"Acta Neuropathol"},{"key":"2591_CR19","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.parkreldis.2013.05.007","volume":"19","author":"J Kulisevsky","year":"2013","unstructured":"Kulisevsky J, Fern\u00e1ndez de Bobadilla R, Pagonabarraga J et al (2013) Measuring functional impact of cognitive impairment: validation of the Parkinson\u2019s disease cognitive functional rating scale. Parkinsonism Relat Disord 19:812\u2013817","journal-title":"Parkinsonism Relat Disord"},{"key":"2591_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.47.1.1","volume":"47","author":"I Litvan","year":"1996","unstructured":"Litvan I, Agid Y, Calne D et al (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47:1\u20139","journal-title":"Neurology"},{"key":"2591_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","volume":"27","author":"I Litvan","year":"2012","unstructured":"Litvan I, Goldman JG, Tr\u00f6ster AI et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: movement disorder society task force guidelines. Mov Disord 27:349\u2013356","journal-title":"Mov Disord"},{"key":"2591_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.parkreldis.2020.04.006","volume":"74","author":"WG Meissner","year":"2020","unstructured":"Meissner WG, H\u00f6glinger GU (2020) Looking into the prediagnostic phase of progressive supranuclear palsy. Parkinsonism Relat Disord 74:74\u201375","journal-title":"Parkinsonism Relat Disord"},{"key":"2591_CR23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/mds.23529","volume":"26","author":"M Morelli","year":"2011","unstructured":"Morelli M, Arabia G, Salsone M et al (2011) Accuracy of magnetic resonance parkinsonism index for differentiation of progressive supranuclear palsy from probable or possible Parkinson disease. Mov Disord 26:527\u2013533","journal-title":"Mov Disord"},{"key":"2591_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.parkreldis.2020.10.003","volume":"81","author":"M Moscovich","year":"2020","unstructured":"Moscovich M, Heinzel S, Postuma RB et al (2020) How specific are non-motor symptoms in the prodrome of Parkinson\u2019s disease compared to other movement disorders? Parkinsonism Relat Disord 81:213\u2013218","journal-title":"Parkinsonism Relat Disord"},{"key":"2591_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.parkreldis.2020.03.003","volume":"74","author":"C Painous","year":"2020","unstructured":"Painous C, Mart\u00ed MJ, Simonet C, Garrido A et al (2020) Prediagnostic motor and non-motor symptoms in progressive supranuclear palsy: the step-back PSP study. Parkinsonism Relat Disord 74:67\u201373","journal-title":"Parkinsonism Relat Disord"},{"key":"2591_CR26","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00415-019-09324-x","volume":"266","author":"M Picillo","year":"2019","unstructured":"Picillo M, Cuoco S, Tepedino MF et al (2019) PSP Salerno study group. Motor, cognitive and behavioral differences in MDS PSP phenotypes. J Neurol 266:1727\u20131735","journal-title":"J Neurol"},{"key":"2591_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/jnnp-2019-321354","volume":"91","author":"M Picillo","year":"2020","unstructured":"Picillo M, Tepedino MF, Abate F et al (2020) Midbrain MRI assessments in progressive supranuclear palsy subtypes. J Neurol Neurosurg Psychiatry 91:98\u2013103","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2591_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.parkreldis.2018.07.016","volume":"54","author":"A Quattrone","year":"2018","unstructured":"Quattrone A, Morelli M, Nigro S et al (2018) A new MR imaging index for differentiation of progressive supranuclear palsy parkinsonism from Parkinson\u2019s disease. Parkinsonism Relat Disord 54:3\u20138","journal-title":"Parkinsonism Relat Disord"},{"key":"2591_CR29","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/mds.27621","volume":"34","author":"A Quattrone","year":"2019","unstructured":"Quattrone A, Morelli M, Vescio B et al (2019) Refining initial diagnosis of Parkinson\u2019s disease after follow-up: a 4-year prospective clinical and magnetic resonance imaging study. Mov Disord 34:487\u2013495","journal-title":"Mov Disord"},{"key":"2591_CR30","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/mds.28364","volume":"36","author":"A Quattrone","year":"2021","unstructured":"Quattrone A, Antonini A, Vaillancourt DE et al (2021) A new MRI measure to early differentiate progressive supranuclear palsy from de novo Parkinson\u2019s disease in clinical practice: an international study. Mov Disord 36:681\u2013689","journal-title":"Mov Disord"},{"key":"2591_CR31","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/mds.28992","volume":"37","author":"A Quattrone","year":"2022","unstructured":"Quattrone A, Bianco MG, Antonini A et al (2022) Development and validation of automated magnetic resonance parkinsonism index 2.0 to distinguish progressive supranuclear PalsyParkinsonism from Parkinson\u2019s disease. Mov Disord 37:1272\u20131281","journal-title":"Mov Disord"},{"key":"2591_CR32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/clinchem\/17.4.275","volume":"17","author":"AH Reed","year":"1971","unstructured":"Reed AH, Henry RJ, Mason WB (1971) Influence of statistical method used on the resulting estimate of normal range. Clin Chem 17:275\u2013284","journal-title":"Clin Chem"},{"key":"2591_CR33","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/j.parkreldis.2015.09.041","volume":"22","author":"G Respondek","year":"2016","unstructured":"Respondek G, H\u00f6glinger GU (2016) The phenotypic spectrum of progressive supranuclear palsy. Parkinsonism Relat Disord 22:S34\u2013S36","journal-title":"Parkinsonism Relat Disord"},{"key":"2591_CR34","first-page":"25","volume":"88","author":"JC Richardson","year":"1963","unstructured":"Richardson JC, Steele J, Olszewski J (1963) Supranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia. A clinical report on eight cases of \u201cheterogeneous system degeneration.\u201d Trans Am Neurol Assoc 88:25\u201329","journal-title":"Trans Am Neurol Assoc"},{"key":"2591_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/mds.22946","volume":"25","author":"JD Rohrer","year":"2010","unstructured":"Rohrer JD, Paviour D, Bronstein AM et al (2010) Progressive supranuclear palsy syndrome presenting as progressive nonfluent aphasia: a neuropsychological and neuroimaging analysis. Mov Disord 25:179\u2013188","journal-title":"Mov Disord"},{"key":"2591_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.827338","volume":"13","author":"J S\u00e1nchez-Ruiz de Gordoa","year":"2022","unstructured":"S\u00e1nchez-Ruiz de Gordoa J, Zelaya V, Tellechea-Aramburo P et al (2022) Is the phenotype designation by PSP-MDS criteria stable throughout the disease course and consistent with tau distribution? Front Neurol 13:827338","journal-title":"Front Neurol"},{"key":"2591_CR37","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1007\/s00415-021-10519-4","volume":"268","author":"M Siciliano","year":"2021","unstructured":"Siciliano M, Trojano L, De Micco R et al (2021) Correlates of the discrepancy between objective and subjective cognitive functioning in non-demented patients with Parkinson\u2019s disease. J Neurol 268:3444\u20133455","journal-title":"J Neurol"},{"key":"2591_CR38","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/mds.20478","volume":"20","author":"Y Tsuboi","year":"2005","unstructured":"Tsuboi Y, Josephs KA, Boeve BF et al (2005) Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Mov Disord 20:982\u2013988","journal-title":"Mov Disord"},{"key":"2591_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.11138\/FNeur\/2018.33.1.031","volume":"33","author":"V Valentino","year":"2018","unstructured":"Valentino V, Iavarone A, Amboni M et al (2018) Apathy in Parkinson\u2019s disease: differences between caregiver\u2019s report and self-evaluation. Funct Neurol 33:31\u201335","journal-title":"Funct Neurol"},{"key":"2591_CR40","unstructured":"Wayne PA (2008) Clinical and Laboratory Standards Institute. Defining, establishing, and verifying reference intervals in the clinical laboratory: approved guideline - third edition. CLSI Document, C28-A3"},{"key":"2591_CR41","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/mds.27038","volume":"32","author":"JL Whitwell","year":"2017","unstructured":"Whitwell JL, H\u00f6glinger GU, Antonini A et al (2017) Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? Mov Disord 32:955\u2013971","journal-title":"Mov Disord"},{"key":"2591_CR42","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/brain\/awh488","volume":"128","author":"DR Williams","year":"2005","unstructured":"Williams DR, de Silva R, Paviour DC et al (2005) Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson\u2019s syndrome and PSP-parkinsonism. Brain 128:1247\u20131258","journal-title":"Brain"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-023-02591-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-023-02591-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-023-02591-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T12:00:11Z","timestamp":1675857611000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-023-02591-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["2591"],"URL":"https:\/\/doi.org\/10.1007\/s00702-023-02591-z","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,26]]},"assertion":[{"value":"4 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marta Campagnolo has received travel grants from Lusofarmaco. Roberta Biundo reports honoraria to speak from Bial. She is supported by the Ministry of Health under Grant No. GR-2016\u201302361986. Luca Weis reports no disclosures. Carmelo Fogliano reports no disclosures. Valeria Cianci reports no disclosures. Michela Garon reports no disclosures. Eleonora Fiorenzato reports no disclosures. Florinda Ferreri reports no disclosures. Patrizia Bisiacchi reports no disclosures. Miryam Carecchio reports no disclosures. Angelo Antonini has received compensation for consultancy and speaker related activities from UCB, Boehringer Ingelheim, Ever Pharma, General Electric, Britannia, AbbVie, Kyowa Kirin, Zambon, Bial, Theravance Biopharma, Jazz Pharmaceuticals, Roche, Medscape; he receives research support from Bial, Lundbeck, Roche, Angelini Pharmaceuticals, Horizon 2020\u2014Grant 825785, Horizon2020 Grant 101016902, Ministry of Education University and Research (MIUR) Grant ARS01_01081, Cariparo Foundation, and Movement Ingelheim for legal cases on pathological gambling. All authors declare that they have no conflict of interest in connection with this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was waived by the local Ethics Committee of University of Padova in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}